Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Lupus nephritis: current issues.

C P Mavragani1, H M Moutsopoulos

  • 1Department of Pathophysiology, School of Medicine, National University of Athens, Greece.

Annals of the Rheumatic Diseases
|August 19, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical relevance of nitrated beta 2-glycoprotein I in antiphospholipid syndrome: Implications for thrombosis risk.

Journal of autoimmunity·2021
Same author

Cryoglobulinemic vasculitis in primary Sjögren's Syndrome: Clinical presentation, association with lymphoma and comparison with Hepatitis C-related disease.

Seminars in arthritis and rheumatism·2020
Same author

West Nile Virus infection triggering autoimmune encephalitis: Pathophysiological and therapeutic implications.

Clinical immunology (Orlando, Fla.)·2019
Same author

Severe osteoporosis in a premenopausal woman.

Scandinavian journal of rheumatology·2019
Same author

Evolution from one autoimmune disorder to another. Epitope spreading?

Scandinavian journal of immunology·2018
Same author

The oral mucosa: A barrier site participating in tissue-specific and systemic immunity.

Oral diseases·2018

Cyclophosphamide (CYC) is a key treatment for severe lupus nephritis, but optimal use remains debated. Alternative therapies exist for difficult cases.

Area of Science:

  • Nephrology
  • Immunology
  • Rheumatology

Background:

  • Severe proliferative lupus nephritis requires effective immunosuppression.
  • Cyclophosphamide (CYC) is the standard initial therapy for lupus nephritis.
  • Optimal CYC treatment protocols (route, dose, duration) are debated.

Purpose of the Study:

  • To review current treatment strategies for severe proliferative lupus nephritis.
  • To discuss the role of cyclophosphamide (CYC) and alternative therapies.

Main Methods:

  • Literature review of treatment modalities for lupus nephritis.
  • Analysis of evidence for cyclophosphamide (CYC) efficacy and safety.
  • Evaluation of alternative and advanced therapies for recalcitrant cases.

Related Experiment Videos

Main Results:

  • Cyclophosphamide (CYC) remains a primary treatment despite ongoing controversies.
  • Various alternative agents and strategies are available for refractory lupus nephritis.
  • Newer immunosuppressive, immunomodulating, and biological agents show promise.

Conclusions:

  • Cyclophosphamide (CYC) is the preferred initial treatment for severe proliferative lupus nephritis.
  • Treatment decisions for CYC require careful consideration of route, dose, and duration.
  • Advanced therapies offer options for patients with recalcitrant lupus nephritis.